Eli Lilly and Company $LLY Position Trimmed by Meadowbrook Wealth Management LLC

Meadowbrook Wealth Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 26.3% in the third quarter, Holdings Channel.com reports. The firm owned 2,407 shares of the company’s stock after selling 861 shares during the period. Eli Lilly and Company comprises 3.0% of Meadowbrook Wealth Management LLC’s portfolio, making the stock its 10th largest holding. Meadowbrook Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,785,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in LLY. Integrity Financial Corp WA increased its position in Eli Lilly and Company by 1.3% during the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after buying an additional 8 shares in the last quarter. Willner & Heller LLC raised its stake in Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after buying an additional 9 shares during the last quarter. Aspiring Ventures LLC boosted its holdings in Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after acquiring an additional 9 shares in the last quarter. Wealthspan Partners LLC grew its stake in shares of Eli Lilly and Company by 0.4% in the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after acquiring an additional 9 shares during the last quarter. Finally, Navigoe LLC grew its stake in shares of Eli Lilly and Company by 8.7% in the second quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after acquiring an additional 9 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 over the last three months. Insiders own 0.14% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside from recent levels. Benzinga report
• Positive Sentiment: Pipeline diversification remains a key bullish argument. Investors are highlighting next-generation obesity candidate retatrutide, which has shown greater weight loss in trials than Zepbound and could be filed with regulators in 2027. Lilly is also expanding its early-stage Alzheimer’s research and testing obesity drug eloralintide alongside birth control. Eli Lilly obesity business article
• Positive Sentiment: Growth extends beyond GLP-1 drugs. Jaypirca, Inluriyo and Retevmo could support oncology growth, while a new research and licensing agreement with InnoCare covers as many as five drug targets. Commentators argue that Lilly’s manufacturing expansion and broad pipeline create a growth flywheel beyond Mounjaro and Zepbound. Lilly oncology portfolio article
• Neutral Sentiment: Technical support is being watched. A move around the 50-day moving average may signal short-term stabilization, but technical indicators do not resolve the stock’s valuation or fundamental risks. LLY moving average analysis
• Negative Sentiment: Valuation and competition are weighing on sentiment. Lilly trades at a premium multiple, leaving the shares sensitive to pricing pressure, increased competition in obesity medicines and any slowdown in GLP-1 demand. New WHO childhood-obesity guidance may also create uncertainty around how these therapies are used in younger patients. WHO obesity guidance article

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $18.95 during trading on Thursday, hitting $1,169.77. 3,090,036 shares of the company’s stock traded hands, compared to its average volume of 2,974,879. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The business has a 50-day simple moving average of $1,173.51 and a 200-day simple moving average of $1,094.59. The stock has a market capitalization of $1.10 trillion, a P/E ratio of 39.25, a PEG ratio of 1.42 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. TD Cowen reiterated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Citigroup increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.